Preliminary Evidence for the Clinical Utility of Tactile Somatosensory Assessments of Sport-Related mTBI

McGeown, Joshua P.; Hume, Patria A.; Kara, Stephen; King, Doug; Theadom, Alice

doi:10.1186/s40798-021-00340-8

Sports Medicine - Open

Table 2 Descriptive statistics grouped by recovery trajectory for SR-mTBI patients assessed using BG-SA at initial clinical assessment (n = 79) and at initial and discharge assessments (n = 45)

From: Preliminary Evidence for the Clinical Utility of Tactile Somatosensory Assessments of Sport-Related mTBI

Descriptive statistics for patients assessed with BG-SA at initial SR-mTBI assessment only
	Total (n = 79)	Resolution ≤14 days (n = 22)	Resolution > 14 days (n = 41)	Lost to follow-up (n = 16)
Sex^a
Male	60 (76%)	21.0 (95%)	28 (68%)	11.0 (69%)
Female	19 (24%)	1.0 (5%)	13 (32%)	5.0 (31%)
Sport^a
Rugby codes	54 (68%)	20 (91%)	26 (63%)	8 (50%)
Others	15 (19%)	1 (5%)	10 (24%)	4 (25%)
Football	10 (13%)	1 (5%)	5 (12%)	4 (25%)
Age^b	19.0 [16.0; 23.0]	19.0 [16.0; 23.0]	19.0 [15.0; 23.0]	20.5 [16.8; 30.8]
Days until initial assessment^b	10.0 [5.5; 14.5]	6.5 [4.0; 10.0]*	11.0 [6.0; 17.0]	11.0 [6.0; 14.0]
Days until asymptomatic^b	20.0 [12.0; 34.5]	10.5 [6.0; 12.0]^◊	30.0 [20.0; 45.0]	–
Initial PST^b	11.0 [6.0; 17.0]	6.0 [3.25; 7.0]*^,†	14.0 [7.0; 17.0]^‡	16.0 [10.5; 18.0]
Initial symptom severity^b	20.0 [8.5; 42.0]	8.0 [5.0; 14.3]*^,†	25.0 [13.0; 47.0]^‡	36.0 [23.5; 48.3]
TOJ performance (ms)^b	29.0 [20.3; 40.2]	26.5 [17.1; 32.9]	29.0 [20.5; 40.6]	32.7 [22.5; 53.8]
TOJc performance (ms)^b	59.9 [34.1; 84.4]	57.8 [40.7; 77.5]	63.9 [32.0; 86.2]	54.9 [42.2; 84.1]
DUR performance (ms)^b	50.0 [29.2; 66.7]	50.0 [41.7; 72.9]	50.0 [25.0; 66.7]	45.8 [25.0; 72.9]
Descriptive statistics for participants assessed with BG-SA at initial and discharge SR-mTBI assessments
	Total (n = 45)	Resolution ≤14 days (n = 15)	Resolution > 14 days (n = 30)
Sex^a
Male	35 (78%)	14.0 (93%)	21 (70%)
Female	10 (22%)	1.0 (7%)	9 (30%)
Sport^a
Rugby codes	33 (73%)	13 (87%)	20 (66%)
Others	8 (18%)	1 (7%)	7 (23%)
Football	4 (9%)	1 (7%)	3 (10%)
Age^b	19.0 [16.0; 23.0]	19.0 [15.5; 23.0]	19.5 [16.0; 24.0]
Days until initial assessment^b	10.0 [5.0; 12.0]	10.0 [4.0; 10.0]^◊	11.0 [6.0; 16.5]
Days until asymptomatic^b	20.0 [12.0; 32.0]	10.0 [5.0; 12.0]^◊	27.5 [20.0; 42.5]
Initial PST^b	7.0 [5.0; 14.0]	5.0 [2.5; 7.0]^◊	11.0 [6.25; 17.0]
Discharge PST^b	1.0 [0.0; 2.0]	0.0 [0.0; 1.0]^◊	1.0 [0.25; 3.0]
Initial symptom severity^b	15.0 [7.0; 29.0]	7.0 [3.0; 11.0]^◊	22.0 [10.5; 44.5]
Discharge symptom severity^b	1.0 [0.0; 2.0]	0.0 [0.0; 1.0]^◊	1.0 [0.25; 4.0]
TOJ performance (ms)^b	27.2 [18.2; 36.8]	24.7 [15.7; 31.9]^◊	28.3 [20.2; 40.4]
TOJc performance (ms)^b	55.6 [34.9; 82.5]	51.3 [42.3; 60.5]^◊	66.1 [32.7; 85.3]
DUR performance (ms)^b	50.0 [25.0; 66.7]	41.7 [29.2; 54.2]^◊	50.0 [29.2; 66.7]

Notes: ^aFrequency (%), ^bmedian [25th percentile; 75th percentile], *Dunn’s post hoc comparison of Kruskal-Wallis tests p < 0.05 ≤ 14-day vs > 14-day resolution, ^†Dunn’s post hoc comparison of Kruskal-Wallis tests p < 0.05 ≤ 14 days vs lost to follow-up, ^‡Dunn’s post hoc comparison of Kruskal-Wallis tests > 14-day resolution vs lost to follow-up, ^◊Mann-Whitney U p < 0.05 for ≤14-day vs > 14-day resolution

Back to article page